Actinium Pharmaceuticals Appoints Matt David as Chief Financial Officer

Dr. David arrives at Actinium from CorMedix Inc., where he served as Executive Vice President and Chief Business Officer. During his tenure there, he played a central role in the FDA approval and commercial launch of DefenCath, as well as the company’s expansion into a diversified specialty pharmaceutical firm. His background spans more than 20 years, including roles in healthcare investment banking at firms like BofA Merrill Lynch and Piper Jaffray, alongside his clinical training as a surgeon.

Chairman and CEO Sandesh Seth noted that David’s combination of medical expertise and Wall Street experience will be critical as the company pushes forward with its lead programs, including ATNM-400 and Actimab-A. For his part, David pointed to the company’s specialized work in actinium-225 as a key factor in his decision to join the leadership team. He will now manage the company's financial operations while supporting the development of its radiopharmaceutical portfolio, which targets both solid tumors and hematologic malignancies.